![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Theratechnologies’ HIV Candidate Meets Primary Endpoint in Phase 3
Theratechnologies’ HIV Candidate Meets Primary Endpoint in Phase 3
May 31, 2016
Theratechnologies’ Phase 3 trial for HIV candidate ibalizumab met its primary endpoint a Phase 3 trial.
Preliminary results show that 82.5 percent of patients enrolled in the study saw a decreased viral load following seven days of treatment, a result that is statistically significant and “better than results observed during the control period.”
Upcoming Events
-
21Oct